Lung Cancer Trials Ask AI to find trials
Active Not RecruitingNot applicableNCT01696994
Official study title

Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)

Study summary

This clinical trial studies whether screening methods used to diagnose cancer of the prostate, lung, colon, rectum, or ovaries can reduce deaths from these cancers. Screening tests may help doctors find cancer cells early and plan better treatment for ovarian cancer. The ovarian cancer screening tests are part of a trial that addresses the screening of four cancer sites, each with their own results record: prostate (NCT00002540), lung (NCT01696968), colorectal (NCT01696981), and ovarian (NCT01696994).

Ask AI to explain this study
Start here

Key things to know

Main goalScreening

This describes the study’s primary purpose.

What is being studiedLaboratory Biomarker Analysis and Screening Questionnaire Administration

Plus 1 other study approaches.

Who it may be forOvarian Carcinoma · Ovarian Germ Cell Tumor

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jul 24, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?National Cancer Institute (NCI)

Study sponsor

01
Study overview

What this study is about

Purpose
Screening
Study type
Interventional
Phase
Not applicable
Sponsor
National Cancer Institute (NCI)
Interventions being studied
Other: Laboratory Biomarker Analysis; Other: Screening Questionnaire Administration; Procedure: Ultrasound Imaging
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

The sponsor has not listed detailed inclusion criteria.

Reasons someone may not be able to joinExclusion criteria
  • Women who at the time of randomization are less than 55 or greater than or equal to 75 years of age
  • Individuals undergoing treatment for cancer at this time, excluding basal-cell and squamous-cell skin cancer
  • Individuals with known prior cancer of the colon, rectum, lung, or ovary
  • This includes primary or metastatic PLCO cancers
  • Individuals with previous surgical removal of the entire colon or one lung
  • Until October 1996, women with previous surgical removal of both ovaries were excluded from the trial. In order to increase the enrollment of women into the trial, beginning in October 1996, these women were no longer excluded for this reason.
  • Individuals who are participating in another cancer screening or cancer primary prevention trial
  • Prior to April 1, 1999 women were excluded from the trial if they were currently taking or had taken Tamoxifen or Evista\\Raloxifene in the past 6 months. As of April 1999 based on a decision from the PLCO Ovary Subcommittee, women who have or are currently taking Tamoxifen or Evista\\Raloxifene are not excluded from participation.
  • Individuals who are unwilling or unable to sign the informed consent form
  • Individuals who have had a colonoscopy, sigmoidoscopy, or barium enema in the past three years

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • National Institutes of Health Clinical CenterBethesda, Maryland

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 24, 2026. Always confirm current availability with the study team.

View original record ↗